Comparison of Contemporary Transcatheter Heart Valve Prostheses: Data from the German Aortic Valve Registry (GARY)

Overview

Journal Clin Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2023 Jul 18

PMID 37462856

Authors

Tanja K Rudolph

Eva Herrmann

Dimitria Bon

Thomas Walther

Timm Bauer

Stephan Ensminger

Christian Frerker

Andreas Beckmann

Helge Mollmann

Raffi Bekeredjian

Friedhelm Beyersdorf

Christian Hamm

Stephan Baldus

Andreas Boning

Jan Gummert

Volker Rudolph

Sabine Bleiziffer

Affiliations

Soon will be listed here.

Abstract

Background: Various second-generation transcatheter heart valve (THV) prostheses with high clinical efficacy and safety are available, but there is limited large-scale data available comparing their hemodynamic performance and clinical implications.

Objective: To compare the hemodynamic performance and short-term clinical outcome of four second-generation THV prostheses.

Methods: 24,124 patients out of the German Aortic Valve Registry who underwent transfemoral transcatheter aortic valve implantation (TAVI) (Evolut™ R n = 7028, Acurate neo™ n = 2922, Portico n = 878 and Sapien 3 n = 13,296) were included in this analysis. Propensity-score weighted analysis was performed to control for differences in age, left ventricular function, STS score and sex. Primary endpoint was survival at one-year, secondary endpoints were 30 days survival, pre-discharge transvalvular gradients, paravalvular leakage and peri-procedural complications.

Results: Thirty-day and one-year survival were not significantly different between the four patient groups. Transvalvular gradients in Evolut™ R and Acurate neo™ were significantly lower as compared to Portico and Sapien 3 at hospital discharge. This difference exists across all annulus sizes. Paravalvular leakage ≥ II occurred significantly less often in the Sapien 3 group (1.2%, p < 0.0001). Rate of severe procedural complications was low and comparable in all groups. Permanent pacemaker implantation rate at one year was lowest in the ACUARATE neo group (13.0%) and highest in the Evolut™ R group (21.9%).

Conclusion: Albeit comparable short-term clinical outcomes there are certain differences regarding hemodynamic performance and permanent pacemaker implantation rate between currently available THV prostheses which should be considered for individual prosthesis selection.

Citing Articles

Early clinical and hemodynamic outcomes of balloon-expandable versus self-expanding transcatheter aortic valve replacement in patients with large aortic annulus: a study-level meta-analysis.

Yamashita Y, Sicouri S, Baudo M, Dokollari A, Ridwan K, Rodriguez R Indian J Thorac Cardiovasc Surg. 2024; 40(6):696-706.

PMID: 39416329 PMC: 11473460. DOI: 10.1007/s12055-024-01770-1.

Comparing balloon-expandable and self-expanding transfemoral transcatheter aortic valve replacement based on subgroups in Germany 2019/2020.

Oettinger V, Hilgendorf I, Wolf D, Rilinger J, Maier A, Zehender M Clin Res Cardiol. 2023; 113(1):168-176.

PMID: 37982864 PMC: 10808194. DOI: 10.1007/s00392-023-02326-w.

References

Kim W, Praz F, Blumenstein J, Liebetrau C, Gaede L, Van Linden A . Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation. Catheter Cardiovasc Interv. 2016; 89(1):E38-E43. DOI: 10.1002/ccd.26464. View

Egron S, Fujita B, Gullon L, Pott D, Schmitz-Rode T, Ensminger S . Radial Force: An Underestimated Parameter in Oversizing Transcatheter Aortic Valve Replacement Prostheses: In Vitro Analysis with Five Commercialized Valves. ASAIO J. 2017; 64(4):536-543. DOI: 10.1097/MAT.0000000000000659. View

Kapadia S, Huded C, Kodali S, Svensson L, Tuzcu E, Baron S . Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. J Am Coll Cardiol. 2018; 72(20):2415-2426. DOI: 10.1016/j.jacc.2018.08.2172. View

Abdel-Wahab M, Neumann F, Mehilli J, Frerker C, Richardt D, Landt M . 1-Year Outcomes After Transcatheter Aortic Valve Replacement With Balloon-Expandable Versus Self-Expandable Valves: Results From the CHOICE Randomized Clinical Trial. J Am Coll Cardiol. 2015; 66(7):791-800. DOI: 10.1016/j.jacc.2015.06.026. View

Mollmann H, Linke A, Holzhey D, Walther T, Manoharan G, Schafer U . Implantation and 30-Day Follow-Up on All 4 Valve Sizes Within the Portico Transcatheter Aortic Bioprosthetic Family. JACC Cardiovasc Interv. 2017; 10(15):1538-1547. DOI: 10.1016/j.jcin.2017.05.021. View

Wendler O, Schymik G, Treede H, Baumgartner H, Dumonteil N, Neumann F . SOURCE 3: 1-year outcomes post-transcatheter aortic valve implantation using the latest generation of the balloon-expandable transcatheter heart valve. Eur Heart J. 2017; 38(36):2717-2726. PMC: 5837400. DOI: 10.1093/eurheartj/ehx294. View

Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V . Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement With the SAPIEN 3. JACC Cardiovasc Interv. 2016; 9(21):2200-2209. DOI: 10.1016/j.jcin.2016.08.034. View

Lanz J, Kim W, Walther T, Burgdorf C, Mollmann H, Linke A . Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. Lancet. 2019; 394(10209):1619-1628. DOI: 10.1016/S0140-6736(19)32220-2. View

Mauri V, Kim W, Abumayyaleh M, Walther T, Moellmann H, Schaefer U . Short-Term Outcome and Hemodynamic Performance of Next-Generation Self-Expanding Versus Balloon-Expandable Transcatheter Aortic Valves in Patients With Small Aortic Annulus: A Multicenter Propensity-Matched Comparison. Circ Cardiovasc Interv. 2017; 10(10). DOI: 10.1161/CIRCINTERVENTIONS.117.005013. View

10.

Kodali S, Pibarot P, Douglas P, Williams M, Xu K, Thourani V . Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J. 2014; 36(7):449-56. DOI: 10.1093/eurheartj/ehu384. View

11.

Leon M, Smith C, Mack M, Makkar R, Svensson L, Kodali S . Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016; 374(17):1609-20. DOI: 10.1056/NEJMoa1514616. View

12.

Thourani V, Kodali S, Makkar R, Herrmann H, Williams M, Babaliaros V . Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016; 387(10034):2218-25. DOI: 10.1016/S0140-6736(16)30073-3. View

13.

Ashauer J, Bonaros N, Kofler M, Schymik G, Butter C, Romano M . Balloon-expandable transcatheter aortic valve implantation with or without pre-dilation - results of a meta-analysis of 3 multicenter registries. BMC Cardiovasc Disord. 2019; 19(1):172. PMC: 6642534. DOI: 10.1186/s12872-019-1151-y. View

14.

Mollmann H, Hengstenberg C, Hilker M, Kerber S, Schafer U, Rudolph T . Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled in the SAVI TF registry. EuroIntervention. 2017; 13(15):e1764-e1770. DOI: 10.4244/EIJ-D-17-00628. View

15.

Husser O, Kim W, Pellegrini C, Holzamer A, Walther T, Mayr P . Multicenter Comparison of Novel Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves. JACC Cardiovasc Interv. 2017; 10(20):2078-2087. DOI: 10.1016/j.jcin.2017.06.026. View

16.

Durko A, Reardon M, Kleiman N, Popma J, Van Mieghem N, Gleason T . Neurological Complications After Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. J Am Coll Cardiol. 2018; 72(18):2109-2119. DOI: 10.1016/j.jacc.2018.07.093. View

17.

Hamm C, Mollmann H, Holzhey D, Beckmann A, Veit C, Figulla H . The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J. 2013; 35(24):1588-98. PMC: 4065384. DOI: 10.1093/eurheartj/eht381. View

18.

Butter C, Bramlage P, Rudolph T, Jacobshagen C, Rothe J, Treede H . Balloon expandable transcatheter aortic valve implantation via the transfemoral route with or without pre-dilation of the aortic valve - rationale and design of a multicentre registry (EASE-IT TF). BMC Cardiovasc Disord. 2016; 16(1):223. PMC: 5111278. DOI: 10.1186/s12872-016-0390-4. View

19.

Fujita B, Schmidt T, Bleiziffer S, Bauer T, Beckmann A, Bekeredjian R . Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1-year outcome. Eur J Cardiothorac Surg. 2019; 57(1):151-159. DOI: 10.1093/ejcts/ezz168. View

20.

Reardon M, Van Mieghem N, Popma J, Kleiman N, Sondergaard L, Mumtaz M . Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017; 376(14):1321-1331. DOI: 10.1056/NEJMoa1700456. View